Semaglutide Dosage Chart: Dosing, Escalation, and Maintenance

Whether you're starting semaglutide treatment for chronic weight management or glycemic control, understanding the dosing schedule is essential. Semaglutide dosing varies depending on the condition being treated and individual response, which means there's no universal "one size fits all" approach. This semaglutide dosage chart walks you through every escalation step, explains what to expect at each dose, and covers critical safety details you need to know.

The primary indications for semaglutide are weight reduction in adults with obesity (or overweight with at least one weight-related comorbidity) and improved glycemic control in type 2 diabetes. Adolescents aged 12 and older may also be eligible for obesity treatment under specific brands.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist used for weight management and blood sugar control. It mimics the GLP-1 hormone in the body, activating receptors in the brain involved in regulating appetite and reducing caloric intake. This appetite suppression is one of the primary drivers behind its effectiveness for helping people lose weight.

On the metabolic side, semaglutide slows gastric emptying to enhance satiety, meaning you feel full longer after eating food. It also improves insulin sensitivity in the body and suppresses glucagon release, which together translate into meaningful improvements in glycemic control. These combined effects, slowing gastric emptying, reducing hunger signals, and optimizing insulin response, are why semaglutide delivers results across both weight loss and diabetes indications.

Standard Dosing Chart for Losing Weight and Dose Escalation

Semaglutide requires gradual dose escalation to minimize gastrointestinal side effects. The starting dose of semaglutide is not intended to provide full therapeutic effect. Instead, it lets your body adjust before gradually increases bring you to a therapeutic level. Patients using semaglutide for weight management often continue titration toward a maintenance dose over 16 or more weeks.

Start semaglutide at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly after the first 4 weeks. Dose increases are typically spaced 4 weeks apart. You reach 2.4 mg weekly by week 17 or later, depending on tolerance.

The initial dose is lower, gradually increased to a maintenance dose. Patients may take longer to reach their target dose based on tolerance. For type 2 diabetes, semaglutide dosing escalates to specific weekly levels as well, though the maximum labeled dose for Ozempic is 2.0 mg weekly rather than 2.4 mg.

1.0 mg Milestone: What To Expect

The 1.0 mg dose is where most patients notice a real shift. Weight loss becomes more visible, often several percent of baseline body weight, and HbA1c reductions of 1–1.5% are common in clinical trials. This is where the body responds to the medication's full therapeutic range.

However, this milestone also comes with a higher likelihood of gastrointestinal side effects. Nausea, abdominal pain, diarrhea, and constipation tend to peak during escalation to 1.0 mg. Mild nausea often improves within a few days after dose escalation. Some patients report fatigue related to reduced caloric intake and changes in sleep quality. Dietary adjustments, such as smaller meals and increased hydration, can help your body adapt during this titration phase.

Ozempic vs Wegovy: Same Dose, Different Goals, and Higher Doses

Ozempic and Wegovy contain the exact same molecule. At the same dose, the drug behaves identically in your body. The difference lies in approved indications and dosing ceilings.

• Ozempic is approved for type 2 diabetes with a maximum dose of 2.0 mg weekly.

• Wegovy is approved for chronic weight management with a standard maintenance of 2.4 mg weekly and a maximum weekly dosage of semaglutide injection at 7.2 mg.

• Oral Wegovy (Rybelsus for diabetes) has its own escalation. Oral semaglutide starts at 3 mg daily, while injectable starts at 0.25 mg weekly. Wegovy is approved for a maximum daily dose of 25 mg for oral tablets. Oral semaglutide requires fasting for 30 minutes before eating food to ensure absorption.

Injectable semaglutide is absorbed consistently compared to oral semaglutide, and injectable semaglutide is typically more effective for weight loss. When switching from injectable to oral semaglutide, specific prescribing guidance must be followed. Always consult your healthcare provider before any formulation change.

Managing Dose Increases and Dose Escalation Side Effects

Gastrointestinal side effects are the most common with semaglutide. Increasing semaglutide dose faster than recommended can increase side effects without improving results, so patience during dose escalation is critical.

Here's how to manage the process:

• Delaying dose escalation is appropriate if you experience persistent GI symptoms. If nausea occurs during semaglutide treatment, clinicians may extend the duration of the current dose for an additional 4 weeks before attempting the next step.

• If a dose is poorly tolerated, hold at a lower dose for at least four weeks before trying again. Clinicians may adjust the semaglutide dosing schedule based on patient tolerance.

• Always contact your healthcare provider before any dose increases or dose adjustments.

• Eat small, frequent meals. Avoiding high-fat and large-volume meals helps reduce severe nausea and other GI symptoms.

• Stay hydrated, especially if vomiting or diarrhea occurs.

Among patients in clinical trials, 3.3% of patients discontinued semaglutide due to GI side effects. Severe GI symptoms may require contacting a healthcare provider immediately, as dehydration from persistent vomiting can lead to complications, particularly in patients with chronic kidney disease or end stage kidney disease.

Missed Dose Guidance

Missed doses of semaglutide should be taken as soon as possible within specific timeframes. Follow these steps:

1. If you remember your missed dose and your next scheduled dose is more than 48 hours away, take the missed dose immediately.

2. If your next dose is less than 48 hours away, skip the missed dose entirely and take your next dose on your regularly scheduled day.

3. Never double doses to catch up. Overlapping doses risks dangerously high plasma levels.

After taking a late dose, resume your regular weekly dose on the same day each week. If you need to shift your injection day, ensure at least 48 hours between the scheduled dose and any adjustment.

When to Consider a Higher Dose or Higher Doses (Including 7.2 mg)

Not everyone reaches their goals at the 2.4 mg maintenance phase. Here's when a higher dose may be warranted:

• At least 4 continuous weeks at 2.4 mg with acceptable tolerability.

• A sustained weight loss plateau despite adherence to lifestyle changes and dietary modification.

• No contraindications, stable comorbid conditions, and a thorough review of medical history.

• Specialist consultation (endocrinologist or obesity medicine physician) is recommended.

FDA approved the 7.2 mg dose on March 19, 2026, under the name "Wegovy HD." The maximum dose for injectable semaglutide is 7.2 mg weekly. In clinical trials, 90.7% achieved 5% or greater weight loss at 7.2 mg, with average weight loss exceeding 20% of baseline body weight. However, 23% of patients at 7.2 mg reported dysaesthesia symptoms, and 3.3% of patients discontinued 7.2 mg due to side effects. Long-term safety data are still emerging, so keeping a dose longer at 2.4 mg before escalation remains prudent.

Monitoring: Glycemic Control and Diabetic Retinopathy

Before initiating once weekly semaglutide, baseline labs should include HbA1c, fasting glucose, body weight, BMI, and renal function. Periodic glucose monitoring during the gradual titration is essential, especially for patients on insulin or sulfonylureas where hypoglycemia risk rises.

Clinical evidence from the SUSTAIN-6 trial demonstrated that rapid HbA1c reductions can trigger early worsening of diabetic retinopathy. Patients with a personal or family history of retinal disease, poor baseline glucose control, or concurrent insulin therapy should undergo an ophthalmologic review before starting semaglutide and at regular intervals during treatment.

Also monitor for signs of pancreatitis, thyroid tumors (particularly medullary thyroid carcinoma), nutritional deficiencies, and kidney function changes.

Compounded Semaglutide: Dosing, Conversion, and Safety

Compounded semaglutide products are not FDA-approved finished drugs. They differ from branded versions in several critical ways:

• Concentration variability: compounded vials come in different mg/mL concentrations with no standardized pen delivery system.

• Salt forms: some contain semaglutide acetate or sodium rather than the base molecule, which can affect dosing calculations.

• Overdose risk: the FDA has issued warnings about dosing errors with compounded injectable semaglutide, primarily from unit-to-mg miscalculations and incorrect syringe volumes.

Before drawing any dose from a compounded vial, verify the vial concentration (mg/mL), the exact volume to draw, and the syringe type. Using a GLP-1 dose calculator specifically designed for compounded vials can reduce errors. Have your provider or pharmacist demonstrate the correct technique, and always confirm your prescribed dose matches what you're drawing up.

Special Situations and Practical Tips

• Rotate your injection site weekly between the abdomen, thigh, and upper arm. Avoid injecting into bruised or irritated skin.

• Before major surgery: discuss holding your dose with your surgeon and anesthesiologist. Semaglutide's effect on slowing gastric emptying raises concerns about pulmonary aspiration during deep sedation and general anesthesia. Holding the dose reduces risk of aspiration events related to delayed gastric emptying.

• Hydration: sip water frequently throughout the day, particularly during the titration phase. Electrolyte supplementation may be warranted if vomiting persists.

• Storage: keep your pen in the refrigerator away from the refrigerator cooling element to avoid freezing. Replace the pen cap after each use.

FAQs to Include

Can I start Wegovy at 1.0 mg? No. The FDA label requires initiating at 0.25 mg weekly for the first 4 weeks, regardless of your current dose goals. Skipping the titration phase dramatically increases GI side effects without improving outcomes. The gradual titration exists specifically to let your body adapt.

How fast can I lose weight on semaglutide? In the STEP-1 trial, the average weight loss at the 2.4 mg maintenance dose over 68 weeks was approximately 14.9% of baseline body weight. Within the first 12–20 weeks at therapeutic doses, many patients lose 5–10%. Rate of sustained weight loss depends on the prescribed dose, adherence, baseline weight, and lifestyle changes.

Why does the same dose feel stronger after week two? Semaglutide has a half-life of approximately 7 days, so plasma levels accumulate with each weekly dosage. By the second or third injection at any given dose, drug concentration is notably higher than after the first. This is why your body responds differently even though the weekly dose hasn't changed.

When do dose increases improve weight loss outcomes? When weight loss plateaus, meaning minimal change over 4–8 weeks at your current dose, and tolerability is acceptable. Increasing before your body has fully adapted to the current dose doesn't accelerate results; it just worsens side effects. The dosing schedule is designed to let each level do its work before moving on.

What is the maintenance dose, and when should I reassess? The maintenance dose for weight loss is typically 2.4 mg weekly. Reassess after at least 4 weeks at maintenance. If weight loss has stalled and side effects are manageable, discuss a higher dose with your provider. If you experience diabetic ketoacidosis, severe nausea, or other complications, your provider may recommend stepping back to a lower dose.

References and Safety Notes

The STEP clinical trial program (STEP-1 through STEP-5) provides the primary clinical evidence supporting the 2.4 mg weekly maintenance dose and the dose escalation schedule for weight management. These trials demonstrated that the gradual titration protocol reduces dropout rates and improves tolerability for most patients.

Black box warning: semaglutide carries a boxed warning for thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Additional contraindications and cautions:

• History of pancreatitis or gallbladder disease

• Risk of cardiovascular death should be evaluated in context of overall cardiometabolic profile

• Hypoglycemia risk when combined with insulin or sulfonylureas

• Caution in patients with chronic kidney disease or end stage kidney disease; monitor renal function regularly

• Not established as safe in pregnancy

Always work with your healthcare provider before starting, adjusting, or discontinuing semaglutide. Bookmark this semaglutide dosage chart and revisit it at each step of your titration to stay on track.

Frequently Asked Questions

What is the starting dose of semaglutide and why is it low?

The starting dose is 0.25 mg weekly for 4 weeks. This low dose allows your body to adjust before gradual increases bring you to therapeutic levels, helping minimize gastrointestinal side effects during treatment initiation.

How long does it take to reach the maintenance dose of semaglutide?

Most patients reach the 2.4 mg weekly maintenance dose by week 17 or later. The timeline depends on individual tolerance. Dose increases are typically spaced 4 weeks apart, and patients may take longer based on how well they tolerate escalations.

What is the difference between Ozempic and Wegovy dosing?

Both contain identical semaglutide molecules. Ozempic for diabetes has a maximum dose of 2.0 mg weekly. Wegovy for weight management has a standard maintenance of 2.4 mg weekly with a maximum of 7.2 mg weekly for injectable formulation.

What should I do if I experience nausea during dose escalation?

Mild nausea often improves within days after escalation. Manage it by eating small, frequent meals, avoiding high-fat foods, and staying hydrated. If symptoms persist, your healthcare provider may extend your current dose for four additional weeks before increasing.

What happens at the 1.0 mg dose milestone?

At 1.0 mg, most patients notice significant weight loss and meaningful HbA1c reductions of 1-1.5% in clinical trials. However, gastrointestinal side effects like nausea, abdominal pain, diarrhea, and constipation tend to peak at this escalation level.